Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
Main Author: | |
---|---|
Publication Date: | 2023 |
Other Authors: | , , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | https://hdl.handle.net/10316/114005 https://doi.org/10.3390/pharmaceutics15020306 |
Summary: | Epilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance. |
id |
RCAP_d0120b47479d0283acf89bcd8a8a01ee |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/114005 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?antiseizure drugsepilepsylipid-based nanosystemspolymeric nanoparticlesnanomedicinesnanotechnologyEpilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance.MDPI2023-01-17info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://hdl.handle.net/10316/114005https://hdl.handle.net/10316/114005https://doi.org/10.3390/pharmaceutics15020306eng1999-4923Matias, MarianaSantos, Adriana O.Silvestre, SamuelAlves, Gilbertoinfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-03-14T10:10:28Zoai:estudogeral.uc.pt:10316/114005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T06:06:51.701158Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
title |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
spellingShingle |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? Matias, Mariana antiseizure drugs epilepsy lipid-based nanosystems polymeric nanoparticles nanomedicines nanotechnology |
title_short |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
title_full |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
title_fullStr |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
title_full_unstemmed |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
title_sort |
Fighting Epilepsy with Nanomedicines-Is This the Right Weapon? |
author |
Matias, Mariana |
author_facet |
Matias, Mariana Santos, Adriana O. Silvestre, Samuel Alves, Gilberto |
author_role |
author |
author2 |
Santos, Adriana O. Silvestre, Samuel Alves, Gilberto |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Matias, Mariana Santos, Adriana O. Silvestre, Samuel Alves, Gilberto |
dc.subject.por.fl_str_mv |
antiseizure drugs epilepsy lipid-based nanosystems polymeric nanoparticles nanomedicines nanotechnology |
topic |
antiseizure drugs epilepsy lipid-based nanosystems polymeric nanoparticles nanomedicines nanotechnology |
description |
Epilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-01-17 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://hdl.handle.net/10316/114005 https://hdl.handle.net/10316/114005 https://doi.org/10.3390/pharmaceutics15020306 |
url |
https://hdl.handle.net/10316/114005 https://doi.org/10.3390/pharmaceutics15020306 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1999-4923 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833602580412891136 |